Previous 10 | Next 10 |
The following slide deck was published by Paratek Pharmaceuticals, Inc. in conjunction with their 2019 Q4 earnings Read more ...
BOSTON, Feb. 26, 2020 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases or other public health threats for civilian, gov...
Paratek Pharmaceuticals, Inc. (PRTK) Q4 2019 Earnings Conference Call February 25, 2020, 16:30 ET Company Participants Ben Strain - Executive Director, IR & Corporate Communications Evan Loh - CEO & Director Adam Woodrow - Chief Commercial Officer & VP Randall Brenn...
Gainers: WW +9.3% . INSP +8.2% . MTDR +7.5% . PRTK +5.5% . ALRM +5.2% . More news on: WW International, Inc., Inspire Medical Systems, Inc., Matador Resources Company, Stocks on the move, , , News on ETFs Read more ...
Paratek Pharmaceuticals (NASDAQ: PRTK ): Q4 GAAP EPS of -$0.81 beats by $0.16 . Revenue of $8.97M (-47.2% Y/Y) misses by $5.86M . Shares +5% . Press Release More news on: Paratek Pharmaceuticals, Inc., Earnings news and commentary, Stocks on the move, Healthcare stocks news, , ...
-- Paratek Expects Full Year 2020 Total Revenues to be Between $75 and $80 Million including NUZYRA Net Sales of Approximately $66 Million -- Paratek Now Anticipates its Cash Runway Will Extend Through the End of 2023 with a Pathway to Cash Flow ...
BOSTON, Feb. 24, 2020 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases or other public health threats for civilian, gov...
Original Post Editor's Note : The summary bullets for this article were chosen by Seeking Read more ...
This article is part of a series that provide an ongoing analysis of the changes made to Baupost Group's 13F stock portfolio on a quarterly basis. It is based on Klarman’s regulatory 13F Form filed on 02/13/2020. Please visit our Tracking Seth Klarman’s Baupost Group Holdings ...
Deals and Financings Bio-Thera Solutions (SHA: 688177) of Guangzhou priced its IPO on Shanghai's STAR Board to raise $241 million at a valuation of almost $2 billion. The offering, which placed 60 million shares at RMB32.76 each, was reported to be 3,225 times oversubscribed. Bio-Thera lis...
News, Short Squeeze, Breakout and More Instantly...
Paratek Pharmaceuticals Inc. Company Name:
PRTK Stock Symbol:
NASDAQ Market:
Paratek Pharmaceuticals Inc. Website:
Acushnet Holdings Corp. (GOLF) is expected to report $0.54 for Q3 2023 Paramount Global (PARA) is expected to report $0.09 for Q3 2023 Curis Inc. (CRIS) is expected to report $-2.32 for Q3 2023 Quanta Services Inc. (PWR) is expected to report $1.99 for Q3 2023 GRI Bio Inc. (GRI) i...
Paratek Pharmaceuticals Inc. (PRTK) is expected to report $-0.25 for Q3 2023
BOSTON, Oct. 05, 2023 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases or other public health threats for civilian, government and military ...